Search

Your search keyword '"DeLozier, Amy"' showing total 122 results

Search Constraints

Start Over You searched for: Author "DeLozier, Amy" Remove constraint Author: "DeLozier, Amy" Language english Remove constraint Language: english
122 results on '"DeLozier, Amy"'

Search Results

4. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)

13. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis.

14. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4)*

15. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

16. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.

17. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.

20. Conversion of Functional Assessment of Chronic Illness Therapy–Fatigue to Patient‐Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.

25. Treatment of adult atopic dermatitis patients according to disease characteristics and demographics.

28. Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis.

29. Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis.

31. Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.

35. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulinresistant patients with type 2 diabetes: analysis of a randomized clinical trial.

36. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).

37. Reliability, Validity, and Responsiveness of the Impact of Weight on Self-Perceptions Questionnaire (IW-SP) in Individuals with Type 2 Diabetes and Obesity.

38. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.

39. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.

40. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.

41. Two Phase 3 Trials of Baricitinib for Alopecia Areata.

42. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.

43. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

44. Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort.

45. Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort.

46. Patient-Reported Disease Burden and Unmet Therapeutic Needs in Atopic Dermatitis.

47. Clinical Relevance of Skin Pain in Atopic Dermatitis.

48. Impact of Atopic Dermatitis Lesion Location on Quality of Life in Adult Patients in a Real-world Study.

49. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.

50. First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis.

Catalog

Books, media, physical & digital resources